PRMX, MFLI, ORFG, YESD
ELCR, TCHH, CCTC, GENT, GBTO, KERX
Our Stocks to Watch today include Precious Metals Exchange Corp. (OTC: PRMX), Muscle Flex Inc. (OTC: MFLI), Orofino Gold Corp. (OTC: ORFG), YesDTC Holdings Inc. (OTCBB: YESD), Electric Car Company Inc. (OTCBB: ELCR), Trustcash Holdings Inc. (OTC: TCHH), Clean Coal Technologies Inc. (OTC: CCTC), Gentium S.p.A. (Nasdaq: GENT), Globotek Holdings Inc. (OTCBB: GBTO) and Keryx Biopharmaceuticals Inc. (Nasdaq: KERX).
PRECIOUS METALS EXCHANGE CORPORATION (OTC: PRMX)
"Up 21.43% in morning trading"
Precious Metal Exchange Corp. is a publicly traded company that has a novel approach to gold and silver trading that offers the added convenience and safety of "high tech" bearer certificates. The company has smelting, minting, and plating facilities as well as high tech assay capabilities. Precious Metals Exchange Corp. is in the precious metals refining and recycling sector of the precious metals industry. The Company will provide a convenient, secure and efficient method for customers to sell items containing precious metals. Targeted direct marketing is used to identify potential customers, and a highly automated fulfillment process to ensure their satisfaction through high payouts and quick service. The Company will recycle customers' broken or unwanted jewelry and other items for gold, platinum and silver content, avoiding the risks and environmental costs of mining.
March 30 -
Precious Metals Exchange Corp. Names Head of Business Development Department
Precious Metals Exchange Corp. (OTC: PRMX) announced the hiring of Jason Ford to head the business development department for PRMX. His duties will involve the coordinating of the move to the new Precious Metals Exchange location and completing the first phase of the Company's unique business plan.
Ford attended Northwood University in Dallas, Texas and graduated Magna Cum Laude with a BBA in Business Administration. While attending Northwood on a baseball scholarship, he earned Division I Baseball All American honors and still holds numerous league and school records including the Division I Triple Crown with a single season record batting average of .456. He was also elected to the All Conference Team each season of his playing career and was chosen Most Valuable Player for each season he participated while maintaining a perfect 4.0 GPA. Ford is listed in Who's Who in America.
Ken Dougherty, Chairman and President of Precious Metals, said, "We look forward to Jason coming on board. Jason's past working experience will be an asset to the company's Business Development Department."
Ford has been involved with Caritas Ranch BBQ since 1994 working in all phases of the Boerne, Texas meat packing plant. His business career also includes Territory Manager for Martin Fletcher & Associates in Dallas, as well as the Salad Bowl franchise operation headquartered in Dallas, TX. He is a Licensed Insurance Agent representing Benefit Architects and is in the process of obtaining his Broker-Dealer Certification.
Ford stated, "People need an option for asset protection and PRMX offers the only game in town. The response to PRMX's business plan has been overwhelming and I look forward to perfecting a product that is truly a capital preservation company with the least risk in the market place. PRMX is able to offer services previously unavailable to the consumer. People who are looking for the ultimate protection in these troubled times will find that PRMX has the products that they are looking for and every American needs."
MUSCLE FLEX INCORPORATED (OTC: MFLI)
"Up 8.57% in morning trading"
Muscle Flex Inc. brings new products to market using direct response TV infomercials specializing in the health, fitness, wellness and hygiene sectors. As well, Muscle Flex Inc. develops and creates general television content for network and cable television distribution. Muscle Flex's corporate strategy is to develop new and innovative products for sale and distribution via its proprietary direct response marketing system and the creation of television media and shows for general network and cable broadcast.
April 1 - BRAVADA / Muscle Flex Launches its New Muscle Flex VATA Brasil Ecommerce Website Heading into its April 8, 2010 Official Launch Party with Kim Kardashian
BRAVADA / Muscle Flex Inc. (OTC: MFLI) announced that it has launched its new Muscle Flex VATA Ecommerce website for its Muscle Flex VATA Brasil Sports and Active Wear Collection at www.MuscleFlexVATA.net ahead of its April 8 BRAVADA International official launch party with Kim Kardashian. The new Muscle Flex VATA website, which will be www.MuscleFlexVATA.com shortly, features over 1500 product images and utilizes the most advanced development source code and technology from search engine optimization, fast and efficient page downloads as well as a next generation shopping cart and order processing system.
BRAVADA / Muscle Flex recently announced its red carpet BRAVADA Couture / Muscle Flex VATA Brasil National Launch Party with Kim Kardashian to be held at The Whisper Lounge located inside The Grove in Los Angeles, California on Thursday April 8, 2010. Kim Kardashian aligned with BRAVADA™ / Muscle Flex® to represent and promote the sassy and sexy Brasilian inspired sports and active wear collection. This gala Hollywood launch party will showcase BRAVADA / Muscle Flex VATA to a cavalcade of national media attendees with a number of additional A-list celebrities expecting to attend. Additional announcements are expected next week.
With the Launch of BRAVADA’s next generation Muscle Flex VATA website, BRAVADA will begin an aggressive and focused online marketing initiative that will begin April 8 with its official launch party. BRAVADA / Muscle Flex will also soon be releasing a companion website, BravadaBrasil.com. MuscleFlexVATA.com will sell the Muscle Flex VATA Brasil Sports and Active Wear Collection exclusively while BravadaBrasil.com shall sell the same Muscle Flex VATA Brasil line with additional Brasilian inspired pieces and accessories. The web strategy associated with its 3 website approach (BravadaCouture.com, Muscle FlexVATA.com and BravadaBrasil.com) is a highly effective next generation method of providing an incredible degree of search engine optimization on a level that is far superior as compared to marketing a single online site. Search engine optimization is the #1 focus of BRAVADA / Muscle Flex’s online ecommerce strategy. This method of multiple online website marketing for search engine optimization is one that involves a process that is considered a next generation approach of optimizing internet presence.
OROFINO GOLD CORPORATION (OTC: ORFG)
Orofino Gold is a precious metals acquisition, exploration, and development company. The Company acquires and explores strategically-located precious metals properties in the historically rich gold bearing jurisdictions of Colombia and Mexico. To this end OROFINO has signed an option agreement to acquire several properties in Colombia. The Company is listed on the Pink Sheets under the symbol ORFG.
March 30 -
Orofino Gold Corp. Announces Exceptional Results Validation due April 8th
Orofino Gold Corp. (OTC: ORFG) ("Orofino Gold" or the "Company") announces that the initial results from mineralized and un-mineralized material samples, as well as selected representative samples collected from its Colombian projects that ran higher than expected in gold, silver and copper will be re-assayed, these results will be available on or before April 8th, 2010. These results will form part of a future NI 43-101 compliant review of previous exploration and field data as well as recommendations and budgets.
YESDTC HOLDINGS INCORPORATED (OTCBB: YESD)
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this marketplace. YesDTC combines both creative talents and financial acumen to create a total package for direct-to-consumer marketing programs. We have formed a strategic partnership with Schulberg Media Works (SMW), one of the pioneering firms in the direct-to-consumer space. SMW's track record is impressive with nearly $1 billion in revenues and a strong track record of industry awards. SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins, PureSleep, among many others.
March 24 - YesDTC Announces the Appointment of William ("Bill") Bush as Chief Financial Officer
YesDTC Holdings, Inc. (OTCBB: YESD), a direct-to-consumer global distributor and marketer of consumer goods and products, today announced the appointment of William ("Bill") Bush as the Company's Chief Financial Officer. Mr. Bush has over 20 years of experience in accounting, financial support and business development, including his most recent success serving as CFO of the leading manufacturer of solar panels in India, helping the company to reach $100 million in sales in its first 15 months of operation.
Additionally, prior to joining YesDTC, Mr. Bush accumulated significant experience in the role of chief financial officer for several high growth software and online media companies with responsibilities for establishing business processes, capital raising, business development and investor relations. Throughout his career, he has also served in the roles of business development and corporate controller and spent seven years in public accounting with Ernst & Young and Price Waterhouse.
Bill holds a B.S. in Business Administration from U.C. Berkeley and is a Certified Public Accountant. He currently serves on the Board of Towerstream, a leading supplier of WiMax services; FindEx.com, a Bible study software provider; and ThinIdentity, a private developer and distributor of virtualization solutions for the medical industry.
ELECTRIC CAR COMPANY INCORPORATED (OTCBB: ELCR)
in morning trading"
Electric Car Company, Inc. is a vehicle conversion company that specializes in electric conversion and manufacturing for the livery and fleet markets including corporate VIP, Party Buses, Municipal Buses and Delivery Vehicles. The company brings together businesses specializing in customizing vehicles and powertrains. This proven business strategy is building a dominating presence in the aftermarket automotive up-fitter segment, including, but not limited to "Pure Electric" cars, liquid propane conversions, limousines & other livery vehicles, specialty fleet vehicles, classic automobiles and custom restorations. The Company fully expects to have the first zero emissions, "Pure Electric" livery vehicle ready to unveil by second quarter of 2010. The long-term strategy is to offer and expand the company's line of products that will revolutionize the specialty automotive vehicle market. Electric Car Company's wholly owned subsidiary, Imperial Coach Works, Inc. and its custom manufacturing division, Imperial Coach Builders, Inc., is a limousine and specialty vehicle manufacturing entity that operates out of a 60,000-square foot facility in Springfield, MO.
March 31 -
Electric Car Company, Inc. Utilizes Grant From the State of Missouri to Increase Efficiency and Lower Overhead Costs
Lean Manufacturing Process Gives Company Competitive Advantage
Electric Car Company, Inc. (OTCBB: ELCR), a vehicle conversion company that specializes in electric conversions and manufacturing for the Livery and Fleet Markets, announces that the Company has utilized a training Grant from the State of Missouri to increase efficiency and lower overhead costs. Implementing "Lean Manufacturing" processes and lowering overall manufacturing costs gives the Company a competitive advantage in the market.
By utilizing the Training Grant awarded to the Company, an independent team of efficiency experts was hired to help overhaul its production process at no cost to The Electric Car Company. The goal is to drastically reduce lead-time and mistakes while improving staffing for the job by reconfiguring traditional assembly lines into productive cells based on one-piece flow.
As a result several steps were taken. The Company has been able to reduce its full time assembly force from 30 down to 19. Any additional labor will be brought in on a job-by-job basis, which also saves on excessive overtime costs. Other areas have been streamlined such as the accounting, marketing and administrative staff that have been reduced by 50%.
The Company has also taken steps to ramp up sales by reducing the salary expense of its sales personnel while increasing the commission structure. This has proven to be very effective with the evidence of the increased sales and contract work brought into the Company in the first quarter of this year.
Mr. Gary Spaniak, CEO of Electric Car Company, Inc. stated, "By utilizing the programs offered by the state, we've been able to continue training at a minimal cost to the company." Mr. Spaniak continued by stating, "The staff is on board with it all. It's not only made us leaner, but it has made us stronger, as well."
TRUSTCASH HOLDINGS (OTCBB: TCHH)
in morning trading"
Through its Trustcash brand and website (www.trustcash.com), the Company is a pioneer of anonymous payment systems for the Internet. It developed a business based on the sale of a stored value card (both virtual and physical) that can be used by consumers to make secure and anonymous purchases on the internet without disclosing their credit card or personal information. Trustcash provides to its customers the Trustcash™ payment card, which is sold in denominations ranging from $10 to $200 online through any of over 500 websites. Trustcash's non-reloadable, virtual Trustcash card is the only "stored value card" that can be purchased where no personal data is stored or available, providing a unique level of both security and privacy to the purchaser.
April 1 -
TrustCash to Address Unbanked Market With TrustCash DEPOSIT™ Product
Trustcash Holdings, Inc. (OTC: TCHH) ("TRUSTCASH") confirms the TrustCashDEPOSIT product will be marketed specifically to address the needs of the unbanked market.
Serving the unbanked is a key part of the TrustCash business plan.
Even though experts differ on just how large this market really is, one thing is clear, the statistics indicate a significant market opportunity:
* CFSI reported that 20 percent of all U.S. households are unbanked. That's about 22.2 million families. Add to that the 19.4 percent of all U.S. families that are underbanked — that's another 22 million families.
* BearingPoint, a management and technology consulting firm, projects an even higher figure — 28 million unbanked U.S. households and 44.7 million underbanked U.S. households.
* Because the breadwinners for unbanked families are typically considered to be low-income wage earners, they are often overlooked by traditional FIs. But CFSI said such families will spend at least $13 billion on more than 340 million alternative financial service transactions — each year. In the Celent LLC research study, Where the Banks Aren't: Nontraditional/Nonbank Advances in Branded Prepaid Cards, Celent Analyst Red Gillen estimated GPR cards for the unbanked population is a potential $31 billion market.
TrustCashDEPOSIT is the smart way for merchant's customers to pay their online invoices in person and can be supported by all major banks in their respective geographic markets. With TrustCashDEPOSIT merchants are guaranteed to receive their funds with none of the risks associated with credit card processing.
CLEAN COAL TECHNOLOGIES (OTC: CCTC)
"Up 23.13% in morning trading"
CCTI, which began operations on September 1, 2007, was formed through the acquisition of Clean Coal Systems, Inc. (CCSI) and a pink sheet shell company that facilitated CCTI's listing on the OTC exchange in early October, 2007 under the symbol "CCTC." CCTI's technology will be marketed through a variety of contractual relationships, including joint ventures, licensing agreements, and build/operate/transfer relationships. CCTI's technology is far superior to coal scrubbing and costs 60-70% less, because it removes pollutants and contaminants that scrubbing does not address. It is truly the "Pollution Solution." The technology allows raw, low-grade coal to be transformed via our multistage patented processes into high grade, clean burning, coal, on an industrial scale.
April 5 -
Clean Coal Technologies, Inc. to Be Featured in Business Week Magazine
Clean Coal Technologies, Inc. (OTC: CCTC) announced that their multi-million-dollar deals in both China and India have been featured in Bloomberg's Business Week magazine, in addition to an overview of its business model, and foreign and domestic plans.
President of Clean Coal Technologies, Inc. Doug Hague stated: "It is a tremendous honor and significant milestone for CCTI to have Bloomberg's Business Week magazine showcase our Company. This further illustrates the increasing awareness and potential of our clean coal solutions to address critical environmental issues.
"We believe that our patented technology, coupled with our unique business model, places CCTI in the forefront of this market, and consequently is in an ideal position to capitalize on its enormous potential.
"In trademarking the name 'PRISTINE' to differentiate the characteristics of our product from traditional coal, we will provide the transitional bridge between existing energy solutions and those of the future.
"This is an exciting time for our company with so many opportunities for growth," Hague concluded. "We look forward to expanding our business model globally and have developed the team and strategic relationships to ensure we get the job done."
GENTIUM S.P.A. (NASDAQ: GENT)
"Up 9.80% in morning trading"
Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.
April 5 -
Skymark Research Initiates Independent Research Coverage on Gentium S.p.A.
Skymark Research, a leading provider of small- and micro-cap independent investment research, initiated coverage on Gentium S.p.A. (Nasdaq: GENT). Skymark Research is currently offering a complimentary trial subscription. To view the company's research, visit www.skymarkresearch.com.
JSC GLOBOTEK HOLDINGS INCORPORATED (OTCBB: GBTO)
"Up 27.78% in morning trading"
JSC Globotek is the developer and owner of a unique technology for the processing of Associated Petroleum Gas (APG) that is carried out at the drilling field by a Modular Mobile Structure. APG is a by-product of crude oil extraction and its flaring currently accounts for approximately 400 million tons of harmful greenhouse gas emissions into the atmosphere every year. APG flaring has far reaching effects on the environment, public health and the economy. Globotek's process involves the use of block-modular mobile complexes that each contain mini gas processing units and can be used in any environment where APG is flared. The advantages of the Globotek APG system are many but can be summarized as speed of construction and installation, small cost and a worldwide market. Russian legislation mandates that all oil fields in Russia must process APG to the international 95% standard by January 2012.
April 5 -
Globotek Signs USD $100 Million Mexico and Colombia Contract
Globotek Holdings, Inc. (OTCBB: GBTO) announced that it has signed yet another multi-year agreement to build one APG processing plant every year for a period of ten years, this time with Colombian oil services giant Colregistros S.A.
According to the company, once built, each of the facilities could add $10 million USD in revenue for a potential ten year revenue of $100 million USD. The client, Colregistros S.A., is a subsidiary of Grupo GPC, a company headquartered in Bogota, Colombia that operates multiple oil fields with E&P assets all over Colombia's main hydrocarbon basin as well as having joint venture interests with oil and gas projects in Mexico. Grupo GPC is dedicated to clean energy solutions and has been actively providing technical solutions to the hydrocarbon industry in the region.
"We are delighted that Colregistros S.A. has chosen our technology over other available options and the agreement allows Globotek immediate penetration into the huge Central and South American oil & gas market — a region we have long been eyeing as part of our global expansion plans," stated Globotek CEO Mr. Lukin.
KERYX BIOPHARMACEUTICALS INCORPORATED (NASDAQ: KERX)
"Up 23.00% in morning trading"
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex™ (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
April 5 -
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.
The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.
A randomized, double-blind Phase 3 trial investigating perifosine in combination with capecitabine (Xeloda®) versus placebo in combination with capecitabine in patients with refractory advanced colorectal cancer is expected to commence in the second quarter of 2010 under a Special Protocol Assessment (SPA) with the FDA.
Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We believe that this Fast Track designation adds substantial value to perifosine's development in refractory advanced colorectal cancer. We intend to initiate the Phase 3 colorectal study in the second quarter, with study completion expected in the second half of 2011. With the SPA and Fast Track designation in place, we believe that commercialization of perifosine in this indication could potentially commence by mid-2012."
In addition to colorectal cancer, perifosine is currently in a Phase 3 trial, under SPA, for the treatment of relapsed/refractory multiple myeloma, with Orphan Drug Status and Fast Track designation granted.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.
ABOUT KRX-0401 (PERIFOSINE)
KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of KRX-0401 on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies.
ABOUT COLORECTAL CANCER
According to the American Cancer Society, colorectal cancer is the third most common form of cancer diagnosed in the United States. It is estimated that over 146,000 people were diagnosed with some form of colorectal cancer with over 49,000 patients dying from colorectal cancer in 2009. Surgery is often the main treatment for early stage colorectal cancer. When colorectal cancer metastasizes (spreads to other parts of the body such as the liver) chemotherapy is commonly used. Treatment of patients with recurrent or advanced colorectal cancer depends on the location of the disease. Chemotherapy regimens (i.e. FOLFOX or FOLFIRI either with or without bevacizumab) have been shown to increase survival rates in patients with metastatic/advanced colorectal cancer. Currently, there are seven approved drugs for patients with metastatic/advanced colorectal cancer: 5-fluorouracil (5-FU), capecitabine (Xeloda®), irinotecan (Camptosar®), oxaliplatin (Eloxatin®), bevacizumab (Avastin®), cetuximab (Erbitux®), and panitumumab (Vectibix®). Depending on the stage of the cancer, two or more of these types of treatment may be combined at the same time or used after one another. For example, FOLFOX combines 5-FU, leucovorin and oxaliplatin and FOLFIRI combines 5-FU, leucovorin and irinotecan. Bevacizumab, a VEGF monoclonal antibody, is commonly administered with chemotherapy. Typically, patients who fail 5-FU, oxaliplatin, irinotecan, and bevacizumab-containing therapies, and who have wild-type KRAS status receive EGFR monoclonal antibody therapy with either cetuximab or panitumumab. Once patients progress on these agents, there are no further standard treatment options.